Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 110

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 110
---
 to obtain an exclusive worldwide license for the production
and commercialization of products with the underlying solution, and then the parties have up to 120 days to negotiate the specific terms
of the license. If the parties fail to negotiate a license within said time period, Yissum shall have no further obligations to the Company.

As of March 31, 2025, we have paid Yissum
a total of $226,000 pursuant to the Research and Option Agreement, as amended.

Subject to receiving a final report as to
the results of the research, we have the exclusive right to enter into a license agreement substantially on the same terms as our current
license agreement with Yissum. The research is continuing.

Our Growth Strategy

The Company plans to recruit an in-house development
team, with members working on several projects simultaneously to save costs and maximize knowledge and expertise. Where relevant stages
of the process will be subcontracted, with members of our team supervising their work.

We aim to progress with the continuous research
and developments activities, to develop additional applications using its technologies and to develop future product candidates and the necessary clinical trials until such time as they can be commercialized through licensing to
larger pharmaceutical companies which will take responsibility for completing advanced stages CTs trials, like Phase III and obtaining
regulatory approvals and marketing the products.

<div align='center'>67</div>

In connection with our Development of Nano Mupirocin, we are planning
to:

| ● | We                                                                                              
 are planning to seek funding through a potential clinical collaboration agreement with the      
 National Institutes of Health (NIH) and/or through partnerships with U.S. government entities   
 and non-profit organizations, such as BARDA and CARB-X in the Unites States and EIC Accelerator 
 gran programs in European Union for conducting Phase I -II Clinical Trials. As part of our      
 efforts, in November 2024 we entered into a Non-Clinical Evaluation Agreement (NCEA) with       
 the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH       
 under the U.S. Department of Health and Human Services (HHS), for non-clinical and pre-clinical 
 services funded by the Division of Microbiology and Infectious Diseases                         |

| ● | Implement                                                                  
 strategy to minimize time to realization of the Nano Mupirocin, including: |

| - | forging strategic                                                                                 
 alliances with established pharmaceutical companies early in the development process, especially